Real‐world study of treatment and outcome of type <scp>B2</scp> + <scp>B3</scp> thymoma: The neglected part of thymoma

Zhao, Ke; Chen, Yeye; Liu, Lei; Wang, Guige; Zhang, Jiaqi; Zhou, Mengxin; Gao, Xuehan; Rao, Ke; Yang, Libing; Guo, Chao; Zhang, Ye; Huang, Che-Jen; Liu, Huan; Li, Shanqing

doi:10.1111/1759-7714.14875

Cited by 3 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modified Masaoka staging is an independent risk factor for the prognosis of all types of thymoma, whether with overall survival or PFS as the endpoint [ 7 , 18 , 20 , 21 ]. This conclusion has also been confirmed in multiple studies targeting type B thymoma [ 5 , 14 , 17 , 22 ]. Similarly, the Masaoka stage was also an important disease prognostic factor for disease progression in our cohort.…”

Section: Discussionsupporting

confidence: 67%

“…The impact of surgical and chemoradiotherapy sequences on prognosis was not compared owing to the small number of cases. However, according to previous studies, preoperative chemotherapy can increase the likelihood of R0 resection, thereby improving patient prognosis [ 17 , 19 ].…”

Section: Discussionmentioning

confidence: 99%

“…Similarly, Lim et al [ 25 ] reported that PORT may benefit patients in Masaoka stage III-IV. Some studies also pointed out that PORT is not an independent prognostic factor for patients with type B thymoma [ 5 , 17 ]. However, no study has demonstrated that PORT can lead to poor prognosis in patients with thymoma.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Zhao,

Liu,

Zhou

et al. 2024

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Objective To explore the risk factors for disease progression after initial treatment of type B thymomas using a predictive nomogram model. Methods A single-center retrospective study of patients with type B thymoma was performed. The Cox proportional hazard model was used for univariate and multivariate analyses. Variables with statistical and clinical significance in the multivariate Cox regression were integrated into a nomogram to establish a predictive model for disease progression. Results A total of 353 cases with type B thymoma were retrieved between January 2012 and December 2021. The median follow-up was 58 months (range: 1–128 months). The 10-year progression-free survival (PFS) was 91.8%. The final nomogram model included R0 resection status and Masaoka stage, with a concordance index of 0.880. Non-R0 resection and advanced Masaoka stage were negative prognostic factors for disease progression (p < 0.001). No benefits of postoperative radiotherapy (PORT) were observed in patients with advanced stage and non-R0 resection (p = 0.114 and 0.284, respectively). Conclusion The best treatment strategy for type B thymoma is the detection and achievement of R0 resection as early as possible. Long-term follow-up is necessary, especially for patients with advanced Masaoka stage and who have not achieved R0 resection. No prognostic benefits were observed for PORT.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Zhao,

Liu,

Zhou

et al. 2024

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

show abstract

Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background This study aimed to examine the treatment and prognosis of patients with type B2 + B3 thymoma and compare it with those patients with type B2 and B3 thymoma. Methods We conducted a retrospective analysis of the results of 39 patients with type B2 + B3 thymoma, 133 patients with type B2 thymoma, and 64 patients with type B3 thymoma. The Kaplan–Meier technique was used to generate survival curves. For multivariate analysis, the Cox proportional hazard model was applied. Results With a median follow‐up of 60 months (range: 1–128 months), the percentage of patients with tumor, node, metastasis (TNM) stage III and IV disease gradually increased from 19.5% to 25.6% to 35.9% among those with histological subtypes B2, B2 + B3, and B3, respectively, p = 0.045. Twenty‐three patients experienced recurrence or metastasis. The total 10‐year progression‐free survival (PFS) rates were 86.0% overall (85.0% in type B2, 87.2% in type B2 + B3, and 87.5% in type B3). Age, R0 resection, and Masaoka–Koga stage were found to have a significant on PFS in all patients. There was no statistically significant difference in PFS between different histotypes of thymoma, p = 0.650. PFS was predicted by R0 resection in all histotypes and by the Masaoka–Koga stage in the type B2 subgroup. Conclusion Combining the two staging methods to guide the diagnosis and treatment of patients with B2 + B3 thymoma is recommended. R0 resection is recommended to reduce recurrence. Patients with B2 + B3 thymoma have a prognosis similar to those with a B2 thymoma or a B3 thymoma alone.

show abstract

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Zhao,

Liu,

Zhou

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Objective To explore the risk factors for disease progression after initial treatment of type B thymomas using a predictive nomogram model. Methods A single-center retrospective study of patients with type B thymoma was performed. The Cox proportional hazard model was used for univariate and multivariate analyses. Variables with statistical and clinical significance in the multivariate Cox regression were integrated into a nomogram to establish a predictive model for disease progression. Results A total of 353 cases with type B thymoma were retrieved between January 2012 and December 2021. The median follow-up was 58 months (range: 1-128 months). The 10-year progression-free survival (PFS) was 91.8%. The final nomogram model included R0 resection status and Masaoka stage, with a concordance index of 0.880. Non-R0 resection and advanced Masaoka stage were negative prognostic factors for disease progression (p < 0.001). No benefits of postoperative radiotherapy (PORT) were observed in patients with advanced stage and non-R0 resection (p = 0.114 and 0.284, respectively). Conclusion The best treatment strategy for type B thymoma is the detection and achievement of R0 resection as early as possible. Long-term follow-up is necessary, especially for patients with advanced Masaoka stage and who have not achieved R0 resection. No prognostic benefits were observed for PORT.

show abstract

Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma

Cited by 3 publications

References 32 publications

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Real‐world study of treatment and outcome of type B2 + B3 thymoma: The neglected part of thymoma

Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model

Contact Info

Product

Resources

About